Navigation Links
AIM-HI Accelerator Fund CEO to Chair Prominent Investment Panel Discussion
Date:1/12/2020

The co-founder and CEO of the AIM-HI Accelerator Fund will chair a panel conversation at an event coinciding with the annual JP Morgan Healthcare Conference. On Sunday, January 12, Sujuan Ba, Ph.D., will lead a morning discussion among highly experienced biotechnology, pharmaceutical and medical technology company investors and advisers at the San Francisco office of international law firm Jones Day.

The investor conversation will be part of the half-day program, Technology Commercialization in Biopharma and Healthcare, being organized by the Chinese Biopharmaceutical Association, USA (CBA), one of the largest Chinese-American professional associations in the country.

The panel’s other scheduled participants are Sequoia Capital Managing Director Lynn Yang, M.B.A., Proxima Ventures Partner Zhe Li, M.B.A., Jones Day Partner Angel Huang, J.D., Liu Chen & Hoffman Founding Partner Lin Sun-Hoffman, Ph.D., J.D., and AIM-HI Accelerator Fund Executive Advisor Rose Wang, M.B.A. Included prominently among the 70-minute discussion will be how the innovative venture philanthropy approach being pioneered by AIM-HI is funding early stage cancer technology start-up companies.

Formed in 2019, the AIM-HI Accelerator Fund invests in pre-seed and seed-stage firms focused on the development of novel therapeutics and diagnostics for cancer patients worldwide. Distinctive among non-profit peers, the organization is guided and supported by a team of cancer research luminaries and inventors who have also made their mark commercially as successful life sciences industry entrepreneurs and investors. Unique also is that AIM-HI proceeds from successful future returns on investment will go toward basic cancer research.

“AIM-HI invests in novel cancer technology innovators at stages considered too early and risky by most other sources,” stated Dr. Ba, who will be in San Francisco for multiple days. “I look forward to highlighting our work and the promising companies we’re supporting throughout the week, including within CBA’s January 12 program.”

About the AIM-HI Accelerator Fund

The AIM-HI Accelerator Fund is a new paradigm through venture philanthropy to fund translational research and start-up oncology companies that commercialize innovative laboratory breakthroughs into new therapies and technologies which can potentially save cancer patients’ lives. It is an independent 501(c)(3) non-profit organization, established with an initial grant from the National Foundation for Cancer Research, with the vision and capacity to accelerate the translation of cancer drug discoveries. For more information, visit https://www.aim-hiaccelerator.org.

Read the full story at https://www.prweb.com/releases/aim_hi_accelerator_fund_ceo_to_chair_prominent_investment_panel_discussion/prweb16828321.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related medicine news :

1. Targeting tumors: Ion beam accelerators take aim at cancer
2. Seven Healthcare Startups Selected to Participate in University City Science Center’s First Digital Health Accelerator
3. Insight Accelerator Labs Advances Member Toward Commercialization
4. OpsAssure Accepted Into Local Accelerator Program
5. Save On Medical Accepted Into Healthbox Accelerator Program
6. The accelerator of molecular motors
7. Achievement Accelerator: Review Examining Brendon Burchard’s Training Program Released
8. Global and Chinese Medical Linear Accelerator Industry – Market Overview, Global Outlook, and Key Players
9. InteractiveStudios Inc. to Supply a Smart Interactive Digital Signage System to the Carleton-led Accelerator
10. Output Medical Joins Insight Accelerator Labs
11. Accepted into 500 Startups Accelerator Program, ZendyHealth.com Reduces The Pain of High Deductibles For Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2020)... ... January 23, 2020 , ... Three leading ... take action to improve diagnostic quality and safety by joining the Coalition ... organizations in healthcare and patient advocacy. , “Diagnostic error is one of the ...
(Date:1/23/2020)... ... , ... Park Avenue based orthopedic surgeon Dr. Jeffrey Schildhorn is ... this new digital portal for patient education to his existing and future NYC patients. ... With over 12 years of hands-on experience, Dr. Schildhorn has built his reputation through ...
(Date:1/23/2020)... Del. (PRWEB) , ... January 23, 2020 , ... ... coaching and risk services for organizations that operate vehicle fleets in North America ... new subscriber-based e-newsletter, will be published monthly with content accessible on the company’s ...
(Date:1/23/2020)... ... January 23, 2020 , ... ... demonstrating that in 2019, the Trump Administration dramatically expanded upon discriminatory, anti-LGBT ... of LGBTQIA+ people in America and around the world. , “During Donald Trump’s ...
(Date:1/23/2020)... Texas (PRWEB) , ... January 23, 2020 , ... ... announced a strategic partnership using SocialClimb’s innovative technology to power the Arrowlytics platform ... practice efficiency and profitability. SocialClimb’s platform integrates seamlessly with practice management systems to ...
Breaking Medicine News(10 mins):
(Date:1/28/2020)... ... January 28, 2020 , ... Advanced foot and ankle specialists ... care for over 20+ years in Livingston County. This medical practice includes four ... ulcer or wound needs. , Many people are not aware that podiatrists treat foot ...
(Date:1/27/2020)... YORK (PRWEB) , ... January 27, 2020 , ... Today, ... kind effort to elevate understanding of and track the current perspectives on patient experience ... patients were largely positive about their own experiences with the healthcare system but had ...
(Date:1/25/2020)... ... January 25, 2020 , ... The Exceptional Women Awardees Foundation ... Program Management, Biosimilars Division of Amgen, has been selected to join their Cohort ... five years of strategic global drug development and life cycle management experience in ...
Breaking Medicine Technology: